A review of atomoxetine effects in young people with developmental disabilities

Michael G. Aman, Tristram Smith, L. Eugene Arnold, Patricia Corbett-Dick, Rameshwari Tumuluru, Jill A. Hollway, Susan L. Hyman, Marissa Imee Mendoza-Burcham, Xueliang Pan, Daniel W. Mruzek, Luc Lecavalier, Lynne Levato, Laura B. Silverman, Benjamin Handen

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

This review summarizes the pharmacokinetic characteristics, pharmacodynamic properties, common side effects, and clinical advantages and disadvantages associated with atomoxetine (ATX) treatment in typically developing children and adults with ADHD. Then the clinical research to date in developmental disabilities (DD), including autism spectrum disorders (ASD), is summarized and reviewed. Of the 11 relevant reports available, only two were placebo-controlled randomized clinical trials, and both focused on a single DD population (ASD). All trials but one indicated clinical improvement in ADHD symptoms with ATX, although it was difficult to judge the magnitude and validity of reported improvement in the absence of placebo controls. Effects of ATX on co-occurring behavioral and cognitive symptoms were much less consistent. Appetite decrease, nausea, and irritability were the most common adverse events reported among children with DD; clinicians should be aware that, as with stimulants, irritability appears to occur much more commonly in persons with DD than in typically developing individuals. Splitting the dose initially, starting below the recommended starting dose, and titrating slowly may prevent or ameliorate side effects. Patience is needed for the slow build-up of benefit. Conclusions: ATX holds promise for managing ADHD symptoms in DD, but properly controlled, randomized clinical trials of atomoxetine in intellectual disability and ASD are sorely needed. Clinicians and researchers should be vigilant for the emergence of irritability with ATX treatment. Effects of ATX on cognition in DD are virtually unstudied.

Original languageEnglish (US)
Pages (from-to)1412-1424
Number of pages13
JournalResearch in Developmental Disabilities
Volume35
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Developmental Disabilities
Disabled Persons
Randomized Controlled Trials
Placebos
Behavioral Symptoms
Neurobehavioral Manifestations
Disabled Children
Appetite
Atomoxetine Hydrochloride
Intellectual Disability
Cognition
Nausea
Pharmacokinetics
Research Personnel
Therapeutics
Research
Population

All Science Journal Classification (ASJC) codes

  • Developmental and Educational Psychology
  • Clinical Psychology

Cite this

Aman, M. G., Smith, T., Arnold, L. E., Corbett-Dick, P., Tumuluru, R., Hollway, J. A., ... Handen, B. (2014). A review of atomoxetine effects in young people with developmental disabilities. Research in Developmental Disabilities, 35(6), 1412-1424. https://doi.org/10.1016/j.ridd.2014.03.006
Aman, Michael G. ; Smith, Tristram ; Arnold, L. Eugene ; Corbett-Dick, Patricia ; Tumuluru, Rameshwari ; Hollway, Jill A. ; Hyman, Susan L. ; Mendoza-Burcham, Marissa Imee ; Pan, Xueliang ; Mruzek, Daniel W. ; Lecavalier, Luc ; Levato, Lynne ; Silverman, Laura B. ; Handen, Benjamin. / A review of atomoxetine effects in young people with developmental disabilities. In: Research in Developmental Disabilities. 2014 ; Vol. 35, No. 6. pp. 1412-1424.
@article{fd3cb37c23654cd69931468196cef053,
title = "A review of atomoxetine effects in young people with developmental disabilities",
abstract = "This review summarizes the pharmacokinetic characteristics, pharmacodynamic properties, common side effects, and clinical advantages and disadvantages associated with atomoxetine (ATX) treatment in typically developing children and adults with ADHD. Then the clinical research to date in developmental disabilities (DD), including autism spectrum disorders (ASD), is summarized and reviewed. Of the 11 relevant reports available, only two were placebo-controlled randomized clinical trials, and both focused on a single DD population (ASD). All trials but one indicated clinical improvement in ADHD symptoms with ATX, although it was difficult to judge the magnitude and validity of reported improvement in the absence of placebo controls. Effects of ATX on co-occurring behavioral and cognitive symptoms were much less consistent. Appetite decrease, nausea, and irritability were the most common adverse events reported among children with DD; clinicians should be aware that, as with stimulants, irritability appears to occur much more commonly in persons with DD than in typically developing individuals. Splitting the dose initially, starting below the recommended starting dose, and titrating slowly may prevent or ameliorate side effects. Patience is needed for the slow build-up of benefit. Conclusions: ATX holds promise for managing ADHD symptoms in DD, but properly controlled, randomized clinical trials of atomoxetine in intellectual disability and ASD are sorely needed. Clinicians and researchers should be vigilant for the emergence of irritability with ATX treatment. Effects of ATX on cognition in DD are virtually unstudied.",
author = "Aman, {Michael G.} and Tristram Smith and Arnold, {L. Eugene} and Patricia Corbett-Dick and Rameshwari Tumuluru and Hollway, {Jill A.} and Hyman, {Susan L.} and Mendoza-Burcham, {Marissa Imee} and Xueliang Pan and Mruzek, {Daniel W.} and Luc Lecavalier and Lynne Levato and Silverman, {Laura B.} and Benjamin Handen",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ridd.2014.03.006",
language = "English (US)",
volume = "35",
pages = "1412--1424",
journal = "Research in Developmental Disabilities",
issn = "0891-4222",
publisher = "Elsevier Inc.",
number = "6",

}

Aman, MG, Smith, T, Arnold, LE, Corbett-Dick, P, Tumuluru, R, Hollway, JA, Hyman, SL, Mendoza-Burcham, MI, Pan, X, Mruzek, DW, Lecavalier, L, Levato, L, Silverman, LB & Handen, B 2014, 'A review of atomoxetine effects in young people with developmental disabilities', Research in Developmental Disabilities, vol. 35, no. 6, pp. 1412-1424. https://doi.org/10.1016/j.ridd.2014.03.006

A review of atomoxetine effects in young people with developmental disabilities. / Aman, Michael G.; Smith, Tristram; Arnold, L. Eugene; Corbett-Dick, Patricia; Tumuluru, Rameshwari; Hollway, Jill A.; Hyman, Susan L.; Mendoza-Burcham, Marissa Imee; Pan, Xueliang; Mruzek, Daniel W.; Lecavalier, Luc; Levato, Lynne; Silverman, Laura B.; Handen, Benjamin.

In: Research in Developmental Disabilities, Vol. 35, No. 6, 01.01.2014, p. 1412-1424.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A review of atomoxetine effects in young people with developmental disabilities

AU - Aman, Michael G.

AU - Smith, Tristram

AU - Arnold, L. Eugene

AU - Corbett-Dick, Patricia

AU - Tumuluru, Rameshwari

AU - Hollway, Jill A.

AU - Hyman, Susan L.

AU - Mendoza-Burcham, Marissa Imee

AU - Pan, Xueliang

AU - Mruzek, Daniel W.

AU - Lecavalier, Luc

AU - Levato, Lynne

AU - Silverman, Laura B.

AU - Handen, Benjamin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - This review summarizes the pharmacokinetic characteristics, pharmacodynamic properties, common side effects, and clinical advantages and disadvantages associated with atomoxetine (ATX) treatment in typically developing children and adults with ADHD. Then the clinical research to date in developmental disabilities (DD), including autism spectrum disorders (ASD), is summarized and reviewed. Of the 11 relevant reports available, only two were placebo-controlled randomized clinical trials, and both focused on a single DD population (ASD). All trials but one indicated clinical improvement in ADHD symptoms with ATX, although it was difficult to judge the magnitude and validity of reported improvement in the absence of placebo controls. Effects of ATX on co-occurring behavioral and cognitive symptoms were much less consistent. Appetite decrease, nausea, and irritability were the most common adverse events reported among children with DD; clinicians should be aware that, as with stimulants, irritability appears to occur much more commonly in persons with DD than in typically developing individuals. Splitting the dose initially, starting below the recommended starting dose, and titrating slowly may prevent or ameliorate side effects. Patience is needed for the slow build-up of benefit. Conclusions: ATX holds promise for managing ADHD symptoms in DD, but properly controlled, randomized clinical trials of atomoxetine in intellectual disability and ASD are sorely needed. Clinicians and researchers should be vigilant for the emergence of irritability with ATX treatment. Effects of ATX on cognition in DD are virtually unstudied.

AB - This review summarizes the pharmacokinetic characteristics, pharmacodynamic properties, common side effects, and clinical advantages and disadvantages associated with atomoxetine (ATX) treatment in typically developing children and adults with ADHD. Then the clinical research to date in developmental disabilities (DD), including autism spectrum disorders (ASD), is summarized and reviewed. Of the 11 relevant reports available, only two were placebo-controlled randomized clinical trials, and both focused on a single DD population (ASD). All trials but one indicated clinical improvement in ADHD symptoms with ATX, although it was difficult to judge the magnitude and validity of reported improvement in the absence of placebo controls. Effects of ATX on co-occurring behavioral and cognitive symptoms were much less consistent. Appetite decrease, nausea, and irritability were the most common adverse events reported among children with DD; clinicians should be aware that, as with stimulants, irritability appears to occur much more commonly in persons with DD than in typically developing individuals. Splitting the dose initially, starting below the recommended starting dose, and titrating slowly may prevent or ameliorate side effects. Patience is needed for the slow build-up of benefit. Conclusions: ATX holds promise for managing ADHD symptoms in DD, but properly controlled, randomized clinical trials of atomoxetine in intellectual disability and ASD are sorely needed. Clinicians and researchers should be vigilant for the emergence of irritability with ATX treatment. Effects of ATX on cognition in DD are virtually unstudied.

UR - http://www.scopus.com/inward/record.url?scp=84900397168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900397168&partnerID=8YFLogxK

U2 - 10.1016/j.ridd.2014.03.006

DO - 10.1016/j.ridd.2014.03.006

M3 - Review article

VL - 35

SP - 1412

EP - 1424

JO - Research in Developmental Disabilities

JF - Research in Developmental Disabilities

SN - 0891-4222

IS - 6

ER -

Aman MG, Smith T, Arnold LE, Corbett-Dick P, Tumuluru R, Hollway JA et al. A review of atomoxetine effects in young people with developmental disabilities. Research in Developmental Disabilities. 2014 Jan 1;35(6):1412-1424. https://doi.org/10.1016/j.ridd.2014.03.006